Patents by Inventor William C. Lumma, Jr.

William C. Lumma, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20170020858
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: February 24, 2016
    Publication date: January 26, 2017
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20150299225
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 22, 2015
    Applicant: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • Compounds for modulating TRPV3 function
    Patent number: 8916550
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: December 23, 2014
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20140155417
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: August 30, 2013
    Publication date: June 5, 2014
    Applicant: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis Underwood, Manfred Weigele, Xiaoguang Zhen
  • Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function
    Patent number: 8552009
    Abstract: The present application relates to compounds of Formula I as defined herein, and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: October 8, 2013
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy S. Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • Compounds for Modulating TRPV3 Function
    Publication number: 20110144135
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: February 7, 2011
    Publication date: June 16, 2011
    Applicant: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
    Patent number: 7893260
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. Suitable compounds include but are not limited to, for example, substituted quinazolin-4-ones of formula I.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: February 22, 2011
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Compounds for Modulating TRPV3 Function
    Publication number: 20100273777
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: April 6, 2010
    Publication date: October 28, 2010
    Applicant: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Compounds for modulating TRPV3 function
    Patent number: 7803790
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: September 28, 2010
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Compounds for Modulating TRPV3 Function
    Publication number: 20100152209
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: November 3, 2006
    Publication date: June 17, 2010
    Applicant: Hydra Biosciences Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Tyrosine kinase inhibitors
    Patent number: 7265134
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: September 4, 2007
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma, Jr.
  • Tyrosine kinase inhibitors
    Patent number: 7115597
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: October 3, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, Jr., John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Jr., Leonard Rodman
  • Tyrosine kinase inhibitors
    Publication number: 20040192926
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 11, 2004
    Publication date: September 30, 2004
    Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma Jr
  • Inhibitors of prenyl-protein transferase
    Patent number: 6376496
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Jeffrey M. Bergman
  • Inhibitors of prenyl-protein transferase
    Patent number: 6358956
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including-farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Gerald E. Stokker
  • Inhibitors of prenyl-protein transferase
    Patent number: 6335343
    Abstract: The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: January 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, Jr., Anthony M. Smith, John T. Sisko
  • Inhibitors of prenyl-protein transferase
    Patent number: 6127390
    Abstract: The present invention is directed to compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: October 3, 2000
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, William C. Lumma, Jr., Anthony W. Shaw, John T. Sisko, Thomas J. Tucker
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5977134
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: November 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Terrence M. Ciccarone, Wasyl Halczenko, John H. Hutchinson, William C. Lumma, Jr., Gerald E. Stokker, Craig A. Stump, Theresa M. Williams
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5939439
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Samuel L. Graham, Lekhanh O. Tran, Ian M. Bell, S. Jane deSolms, Robert P. Gomez, Michelle Sparks Kuo, William C. Lumma, Jr., Debra S. Perlow, Anthony W. Shaw, John S. Wai, Steven D. Young
  • Benzoxazinones as inhibitors of HIV reverse transcriptase
    Patent number: 5811423
    Abstract: Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: September 22, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Steven D. Young, Linda S. Payne, Susan F. Britcher, Lekhanh O. Tran, William C. Lumma, Jr.